Arvinas gets FDA approval for VEPPANU (vepdegestrant) in ESR1m breast cancer; first PROTAC approved

ARVINAS, INC.

FDA approved VEPPANU for ER+/HER2-, ESR1-mutated advanced/metastatic breast cancer after at least one prior endocrine therapy.
VEPPANU is the first FDA-approved PROTAC degrader; approval came before June 5, 2026 PDUFA date.
Arvinas to receive $50M development milestone payment from collaborator Pfizer upon approval.
Arvinas and Pfizer on track to select third-party for VEPPANU commercialization.
Phase 3 VERITAC-2: vepdegestrant reduced risk of progression or death by 43% vs fulvestrant (HR 0.57, p=0.0001).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.